BRPI0924581A2 - genetically modified plasmodium vivax antigen sequences, vaccine compositions containing recombinant proteins and recombinant viruses expressing these antigens, and dose-boosting malaria vaccination method - Google Patents

genetically modified plasmodium vivax antigen sequences, vaccine compositions containing recombinant proteins and recombinant viruses expressing these antigens, and dose-boosting malaria vaccination method

Info

Publication number
BRPI0924581A2
BRPI0924581A2 BRPI0924581A BRPI0924581A BRPI0924581A2 BR PI0924581 A2 BRPI0924581 A2 BR PI0924581A2 BR PI0924581 A BRPI0924581 A BR PI0924581A BR PI0924581 A BRPI0924581 A BR PI0924581A BR PI0924581 A2 BRPI0924581 A2 BR PI0924581A2
Authority
BR
Brazil
Prior art keywords
boosting
antigens
dose
compositions containing
genetically modified
Prior art date
Application number
BRPI0924581A
Other languages
Portuguese (pt)
Inventor
Bruna De Andrade Pereira
Cristiana Ferreira Alves De Brito
Cristina Lima Carrara
Flávio Da Fonseca Guimarães
Irene Soares
Leoneide Erica Maduro Bouillet
Mauríio Martins Rodrigues
Marisa Cristina Da Fonseca
Oscar Bruna Romero
Ricardo Tostes Gazzinelli
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Publication of BRPI0924581A2 publication Critical patent/BRPI0924581A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0924581A 2009-05-05 2009-05-05 genetically modified plasmodium vivax antigen sequences, vaccine compositions containing recombinant proteins and recombinant viruses expressing these antigens, and dose-boosting malaria vaccination method BRPI0924581A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2009/000130 WO2010127420A1 (en) 2009-05-05 2009-05-05 Genetically modified sequences encoding plasmodium vivax antigens

Publications (1)

Publication Number Publication Date
BRPI0924581A2 true BRPI0924581A2 (en) 2016-07-19

Family

ID=43049863

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924581A BRPI0924581A2 (en) 2009-05-05 2009-05-05 genetically modified plasmodium vivax antigen sequences, vaccine compositions containing recombinant proteins and recombinant viruses expressing these antigens, and dose-boosting malaria vaccination method

Country Status (3)

Country Link
CN (1) CN102575256A (en)
BR (1) BRPI0924581A2 (en)
WO (1) WO2010127420A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055181A2 (en) * 2000-01-31 2001-08-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention Recombinant multivalent malarial vaccines against plasmodium vivax
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines

Also Published As

Publication number Publication date
WO2010127420A9 (en) 2010-12-29
WO2010127420A1 (en) 2010-11-11
CN102575256A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
CY1121528T1 (en) RECOMMENDATED GALLID 3 HARPETIC CARRIERS (MDV SEROTYP 2) EXPRESSING ANTIGENS OF BIRD PATHOGENS AND THEIR USES
CY1120430T1 (en) RECOMMENDED CDV COMPOSITIONS AND USES OF THESE
ECSP088231A (en) MALARIA VACCINES BASED ON ADENOVIRAL VECTORS
ZA201109444B (en) Vaccines against herpes simplex virus type 2:compositions and methods for eliciting an immune response
HK1210702A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
WO2015052543A3 (en) Malaria vaccination
EA201400912A1 (en) RECOMBINANT POXVIRUS VECTORS, EXPRESSING PROTEINS OF THE RABOR AND OX40 VIRUS, AND VACCINES ESTABLISHED ON THEIR BASIS
HK1179508A1 (en) Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
IL214385A (en) Inactivated dengue virus vaccine with aluminum-free adjuvant
MX355501B (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria.
ZA201201714B (en) Protein matrix vaccines of improved immunogenicity
HK1165694A1 (en) Codon-optimized hepatitis b virus core antigen (hbcag) (hbcag)
PL2658570T3 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MA37749A1 (en) Vaccines against bluetongue and African horse sickness virus
PL2575872T3 (en) Concentration of influenza vaccine antigens without lyophilization
CL2012003219A1 (en) Recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a rabies virus; preparation process of said parapoxvirus; immunogenic composition; use of the composition to induce immune response against rabies virus in an animal.
ZA201008125B (en) Inactivated live-attenuated bluetongue virus vaccine
EP2298910A4 (en) Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof
BRPI0924581A2 (en) genetically modified plasmodium vivax antigen sequences, vaccine compositions containing recombinant proteins and recombinant viruses expressing these antigens, and dose-boosting malaria vaccination method
WO2009023308A3 (en) Genetically modified babesia parasites expressing protective tick antigens and uses thereof
EP2195019A4 (en) Method of eliciting an immune response against pandemic influenza virus
UY31574A1 (en) VACCINES AGAINST MALARIA
EP2785369A4 (en) Immunogenic plasmodium falciparum antigen compositions and uses thereof
EP2451478A4 (en) Plasmodium falciparum sporozoite and liver stage antigens
PL2409987T3 (en) Ribosomal P protein complex from Plasmodium falciparum as antigen in vaccines against malaria

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.